Graviss Lab

12676

Citations

59

h-index

About the Lab

The Graviss lab uses epidemiology, biostatistics, molecular diagnostics, and population-based surveillance to study a variety of infectious agents, including Mycobacterium tuberculosis. Recent studies from the lab evaluated the new Interferon Gamma Release Assays (IGRAs) in the diagnosis of latent tuberculosis infection and the development and evaluation of point-of-care diagnostic assays for tuberculosis disease.
Pathology News
There’s a New Strep in Town
New study highlights the complexity of human infections caused by a rapidly emerging strep subtype
Improving Vaccine Design with an AI Booster

CEPI awards $34 million to the Houston Methodist Research Institute-led consortium to use artificial intelligence for the design of vaccines to fight diseases with pandemic potential.

Omicron – Ongoing Lessons in a Pandemic

Omicron Demonstrates the Power and Necessity of Genetic Sequencing in a Pandemic

Researchers Uncover Distinct Patterns of a Common Pathology in Dementia

Known as LATE, a very common form of brain pathology affects ~40% of elderly patients. Researchers at Houston Methodist have unraveled several patterns of LATE in the brains of aging and demented patients. These patterns have distinct clinical, pathologic and genetic associations.

Fighting a Deadly Duo
Investigating therapeutics to fight deadly TB/HIV coinfections.
Houston Methodist and Purdue University Make a Breakthrough That May Result in a More Effective Tuberculosis Vaccine

A recombinant bovine adenoviral mucosal vaccine expressing mycobacterial antigen-85B generates robust protection against tuberculosis in mice

Donate to Houston Methodist

With your support, Houston Methodist provides exceptional research, education, and care that is truly leading medicine.

Donate Now